An advanced screen featuring a collection of 27 hard-to-source primary patient Acute Myeloid Leukemia (AML) models, retaining essential blood cancer molecular traits and mutations to support pioneering AML drug development research.
Enrolling until May 15th, 2025
Why choose the Champions AML In Vivo Screen?
Champion’s advanced systemic Acute-Myeloid Leukemia AML Screen features 27 highly specialized models of Acute-Myeloid Leukemia, sourced from primary blood cancer patient biopsies. These extensively characterized models maintain essential AML-specific mutations & molecular signatures. Additionally, several models have undergone prior treatment with advanced therapies such as experimental FLT3 inhibitors, anti-CD33 ADCs, and stem cell transplants, closely simulating real-world clinical outcomes, providing a robust platform for evaluating therapeutic efficacy of AML therapies in clinically relevant settings.
Clinically Relevant Models
Living & diverse bank of primary patient AML models that correlate with clinical outcomes
Pretreated PDX Models
Established from tumor biopsies from patients pretreated with latest generation therapies
Multi-omic Characterization
Clinical annotations coupled with molecular datasets and in vivo responses
Champions' elite AML In Vivo Screen, an advanced platform showcasing primary Acute Myeloid Leukemia (AML) models, each reflecting diverse and complex AML subtypes.
-
Includes models pretreated with advanced therapies like experimental FLT3 inhibitors, experimental anti-CD33 ADC, Stem cell transplant and more.
-
Complete model characterization (clinical data, NGS analysis, proteomics, phospho-proteomics, and kinase activity)
-
Terminal flow cytometry analysis on peripheral blood and bone marrow
-
AML Engraftment Assessement using Champions' Standard systemic AML In Vivo engraftment panel: CD3, CD33, CD34,CD38, mCD45, hCD45, CD117, CD123, Viability Dye
-
Plasma-based Luminex available
Champions' Systemic AML In Vivo Screen
